Mice receiving both IL-32 and anti–PD-1 showed significantly reduced tumor growth compared with mice receiving either monotherapy (Figure 6B) and displayed the most significant increase in CD45+ leukocytes (Figure 6C). This evidence concerns the gene PTPRC and neoplasm.